spironolactone has been researched along with Weight Reduction in 16 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome." | 7.78 | Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012) |
| "Acute congestive heart failure (ACHF) is a state of severe, secondary hyperaldosteronism." | 5.48 | Association Between High-Dose Spironolactone and Decongestion in Patients with Acute Heart Failure: An Observational Retrospective Study. ( Barbetseas, J; Bonou, M; Kapelios, CJ; Lund, LH; Mantzouratou, P; Tzanis, G; Vogiatzi, P, 2018) |
| " Among the treatment groups, EE/CA-metformin may be a more effective therapeutic option than the other protocols and this may be due to the beneficial effect of EE/CA-metformin on insulin resistance." | 5.14 | Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. ( Alacacioglu, A; Kebapcilar, AG; Kebapcilar, L; Sari, I; Taner, CE, 2010) |
| "25% salt in drinking water improved body weight reduction associated with sodium and water retention in hepatocellular carcinoma rats, which was suppressed by treatment with spironolactone, a mineralocorticoid receptor antagonist." | 4.12 | Hepatocellular carcinoma induces body mass loss in parallel with osmolyte and water retention in rats. ( Kidoguchi, S; Kitada, K; Kittikulsuth, W; Kobara, H; Masaki, T; Nakajima, K; Nakano, D; Nishiyama, A; Ohsaki, H; Takahashi, K; Titze, J; Yokoo, T, 2022) |
| "Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome." | 3.78 | Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012) |
| "A high-performance liquid chromatographic (HPLC) method for the simultaneous analysis of triamterene, trichlormethiazide, furosemide and spironolactone is presented for application in the examination of health food supplements advertising weight reduction and in the analysis of pharmaceuticals." | 3.71 | [Simultaneous analysis of four diuretic drugs by HPLC and its application to health food supplements advertising weight reduction]. ( Goto, T; Matsumoto, H; Mikami, E; Ohno, T, 2002) |
| " On long term evaluation in an open design (Phase II), wherein Phase I participants continued Terminalia Arjuna in fixed dosage (500 mg 8-hourly) in addition to flexible diuretic, vasodilator and digitalis dosage for 20-28 months (mean 24 months) on outpatient basis, patients showed continued improvement in symptoms, signs, effort tolerance and NYHA Class, with improvement in quality of life." | 2.68 | Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure. ( Bharani, A; Bhargava, KD; Ganguly, A, 1995) |
| "--Weight loss is an important part of the treatment of obese, hirsute women with PCOS." | 2.44 | [Hirsutism]. ( Pijl, H; van Zuuren, EJ, 2007) |
| "Acne is an off-label use of some COCs." | 1.72 | Female Pelvic Conditions: Polycystic Ovary Syndrome. ( Brady, PH; Gin, GT; Rosenblum, E; Wilkinson, LD, 2022) |
| "Spironolactone treatment resulted in significantly reduced loss of mass during the first week, however, over the following weeks, no differences in mass loss were observed in the groups implanted with blockers, while cortisol-treated fish showed the highest decrease in body mass over time." | 1.72 | Combined antagonist treatment of glucocorticoid and mineralocorticoid receptor does not affect weight loss of fasting rainbow trout but inhibits a fasting-induced elevation of cortisol secretion. ( Pfalzgraff, T; Skov, PV, 2022) |
| "The concomitant use of TLV and conventional diuretics is safe and effective for fluid management after TAR using cardiopulmonary bypass, selective cerebral perfusion, and hypothermic circulatory arrest." | 1.51 | Safety and Effectiveness of Tolvaptan Administration after Total Arch Replacement. ( Iida, Y; Shimizu, H; Yoshitake, A, 2019) |
| "Acute congestive heart failure (ACHF) is a state of severe, secondary hyperaldosteronism." | 1.48 | Association Between High-Dose Spironolactone and Decongestion in Patients with Acute Heart Failure: An Observational Retrospective Study. ( Barbetseas, J; Bonou, M; Kapelios, CJ; Lund, LH; Mantzouratou, P; Tzanis, G; Vogiatzi, P, 2018) |
| "Type 1 diabetes was induced in female Wistar rats by a single tail vein injection of streptozotocin (STZ), and SPL was administrated daily by gavage, from days 3-21." | 1.46 | Aldosterone signaling regulates the over-expression of claudin-4 and -8 at the distal nephron from type 1 diabetic rats. ( González-Ramírez, R; Molina-Jijón, E; Namorado-Tónix, C; Pedraza-Chaverri, J; Reyes, JL; Rodríguez-Muñoz, R, 2017) |
| "Hirsutism is the manifestation of hyperandrogenemia in PCOS." | 1.32 | The treatment of polycystic ovary syndrome. ( Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Kidoguchi, S | 1 |
| Kitada, K | 1 |
| Nakajima, K | 1 |
| Nakano, D | 1 |
| Ohsaki, H | 1 |
| Kittikulsuth, W | 1 |
| Kobara, H | 1 |
| Masaki, T | 1 |
| Yokoo, T | 1 |
| Takahashi, K | 1 |
| Titze, J | 1 |
| Nishiyama, A | 1 |
| Wilkinson, LD | 1 |
| Brady, PH | 1 |
| Gin, GT | 1 |
| Rosenblum, E | 1 |
| Pfalzgraff, T | 1 |
| Skov, PV | 1 |
| Molina-Jijón, E | 1 |
| Rodríguez-Muñoz, R | 1 |
| González-Ramírez, R | 1 |
| Namorado-Tónix, C | 1 |
| Pedraza-Chaverri, J | 1 |
| Reyes, JL | 1 |
| Kapelios, CJ | 1 |
| Bonou, M | 1 |
| Vogiatzi, P | 1 |
| Tzanis, G | 1 |
| Mantzouratou, P | 1 |
| Lund, LH | 1 |
| Barbetseas, J | 1 |
| Drzayich Antol, D | 1 |
| Waldman Casebeer, A | 1 |
| Khoury, R | 1 |
| Michael, T | 1 |
| Renda, A | 1 |
| Hopson, S | 1 |
| Parikh, A | 1 |
| Stein, A | 1 |
| Costantino, M | 1 |
| Stemkowski, S | 1 |
| Bunce, M | 1 |
| Nevo, N | 1 |
| Abu-Abeid, S | 1 |
| Hazzan, D | 1 |
| Lahat, G | 1 |
| Nachmani, I | 1 |
| Eldar, SM | 1 |
| Zhang, L | 1 |
| Xia, X | 1 |
| Zhong, Y | 1 |
| Xie, D | 1 |
| Liu, S | 1 |
| Wang, X | 1 |
| Tu, J | 1 |
| Faconti, L | 1 |
| Mills, CE | 1 |
| Govoni, V | 1 |
| Gu, H | 1 |
| Morant, S | 1 |
| Jiang, B | 1 |
| Cruickshank, JK | 1 |
| Webb, AJ | 1 |
| Lin, J | 1 |
| Wu, YJ | 1 |
| Liang, X | 1 |
| Ji, M | 1 |
| Ying, HM | 1 |
| Wang, XY | 1 |
| Sun, X | 1 |
| Shao, CH | 1 |
| Zhan, LX | 1 |
| Zhang, Y | 1 |
| Czamara, K | 1 |
| Karnas, E | 1 |
| Majka, Z | 1 |
| Wojcik, T | 1 |
| Zuba-Surma, EK | 1 |
| Baranska, M | 1 |
| Kaczor, A | 1 |
| Liu, X | 1 |
| Zhou, F | 1 |
| Yang, Y | 1 |
| Wang, W | 1 |
| Niu, L | 1 |
| Zuo, D | 1 |
| Li, X | 1 |
| Hua, H | 1 |
| Zhang, B | 1 |
| Kou, Y | 1 |
| Guo, J | 1 |
| Kong, F | 1 |
| Pan, W | 1 |
| Gao, D | 1 |
| Meves, JM | 1 |
| Sun, H | 1 |
| Xue, M | 1 |
| Zhang, Q | 1 |
| Wang, Y | 1 |
| Tang, R | 1 |
| Iso, T | 1 |
| Haruyama, H | 1 |
| Sunaga, H | 1 |
| Matsui, H | 1 |
| Matsui, M | 1 |
| Tanaka, R | 1 |
| Umbarawan, Y | 1 |
| Syamsunarno, MRAA | 1 |
| Putri, M | 1 |
| Yamaguchi, A | 1 |
| Hanaoka, H | 1 |
| Negishi, K | 1 |
| Yokoyama, T | 1 |
| Kurabayashi, M | 1 |
| Palomo-Briones, R | 1 |
| Esquivel-González, S | 1 |
| Aizpuru, A | 1 |
| Gómez-Hernández, N | 1 |
| Casas-Flores, S | 1 |
| Barba de la Rosa, AP | 1 |
| Arriaga, S | 1 |
| Peterson, ME | 1 |
| Carothers, MA | 1 |
| Gamble, DA | 1 |
| Rishniw, M | 1 |
| Iida, Y | 1 |
| Yoshitake, A | 1 |
| Shimizu, H | 1 |
| Kebapcilar, L | 1 |
| Taner, CE | 1 |
| Kebapcilar, AG | 1 |
| Alacacioglu, A | 1 |
| Sari, I | 1 |
| Kulshreshtha, B | 1 |
| Gupta, N | 1 |
| Ganie, MA | 1 |
| Ammini, AC | 1 |
| Ajossa, S | 1 |
| Guerriero, S | 1 |
| Paoletti, AM | 1 |
| Orrù, M | 1 |
| Melis, GB | 1 |
| de Resende, MM | 1 |
| Kriegel, AJ | 1 |
| Greene, AS | 1 |
| van Zuuren, EJ | 1 |
| Pijl, H | 1 |
| Bharani, A | 1 |
| Ganguly, A | 1 |
| Bhargava, KD | 1 |
| Ljubicić, N | 1 |
| Bilić, A | 1 |
| Kopjar, B | 1 |
| Goto, T | 1 |
| Mikami, E | 1 |
| Ohno, T | 1 |
| Matsumoto, H | 1 |
| Parikh, SS | 1 |
| Amarapurkar, DN | 1 |
| Viswanath, N | 1 |
| Desai, HG | 1 |
| Kalro, RH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Diuretic and Natriuretic Effect of High-dose Spironolactone in Patients With Acute Heart Failure[NCT04618601] | Phase 4 | 50 participants (Anticipated) | Interventional | 2020-10-20 | Active, not recruiting | ||
| Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy-- a Multicenter Randomized Control Trial[NCT02948998] | Phase 4 | 260 participants (Anticipated) | Interventional | 2018-05-14 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for spironolactone and Weight Reduction
| Article | Year |
|---|---|
[Hirsutism].
Topics: Androgen Antagonists; Androgens; Contraceptives, Oral; Cyproterone Acetate; Female; Hirsutism; Human | 2007 |
4 trials available for spironolactone and Weight Reduction
| Article | Year |
|---|---|
Topics: Adult; Aged; Animals; Astrocytes; Bariatric Surgery; Beta vulgaris; Bioreactors; Biotechnology; Bloo | 2018 |
Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome.
Topics: Adult; Blood Coagulation; Cyproterone Acetate; Estrogens; Ethinyl Estradiol; Female; Fibrin Fibrinog | 2010 |
Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure.
Topics: Adult; Aged; Cardiomyopathy, Dilated; Chemotherapy, Adjuvant; Chronic Disease; Coronary Disease; Cro | 1995 |
Diuretics vs. paracentesis followed by diuretics in cirrhosis: effect on ascites opsonic activity and immunoglobulin and complement concentrations.
Topics: Adult; Aged; Ascites; Ascitic Fluid; Blood Cell Count; Chemotherapy, Adjuvant; Complement C3; Comple | 1994 |
11 other studies available for spironolactone and Weight Reduction
| Article | Year |
|---|---|
Hepatocellular carcinoma induces body mass loss in parallel with osmolyte and water retention in rats.
Topics: Aldosterone; Animals; Carcinoma, Hepatocellular; Diethylnitrosamine; Liver Neoplasms, Experimental; | 2022 |
Female Pelvic Conditions: Polycystic Ovary Syndrome.
Topics: Acne Vulgaris; Anovulation; Female; Finasteride; Gonadotropin-Releasing Hormone; Hirsutism; Humans; | 2022 |
Combined antagonist treatment of glucocorticoid and mineralocorticoid receptor does not affect weight loss of fasting rainbow trout but inhibits a fasting-induced elevation of cortisol secretion.
Topics: Animals; Fasting; Glucocorticoids; Hydrocortisone; Mifepristone; Mineralocorticoid Receptor Antagoni | 2022 |
Aldosterone signaling regulates the over-expression of claudin-4 and -8 at the distal nephron from type 1 diabetic rats.
Topics: Aldosterone; Animals; Claudin-4; Claudins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2017 |
Association Between High-Dose Spironolactone and Decongestion in Patients with Acute Heart Failure: An Observational Retrospective Study.
Topics: Aged; Diuretics; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Retrospective | 2018 |
Safety and Effectiveness of Tolvaptan Administration after Total Arch Replacement.
Topics: Administration, Oral; Aged; Antidiuretic Hormone Receptor Antagonists; Aortic Aneurysm, Thoracic; Bl | 2019 |
Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis.
Topics: Adolescent; Adult; Androgen Antagonists; Female; Glucose Intolerance; Hirsutism; Humans; Hyperglycem | 2012 |
The treatment of polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; | 2004 |
Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy.
Topics: Administration, Oral; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals | 2006 |
[Simultaneous analysis of four diuretic drugs by HPLC and its application to health food supplements advertising weight reduction].
Topics: Chromatography, High Pressure Liquid; Dietary Supplements; Diuretics; Food, Organic; Furosemide; Sod | 2002 |
Ascitic fluid protein and cellular changes during diuretic therapy in cirrhosis of liver.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ascitic Fluid; Blood Proteins; Cell Count; Furosemide; H | 1991 |